Immune Thrombotic Thrombocytopenic Purpura in Elderly Patients: The Roles of PLASMIC and French Scores

Basit Öğe Kaydı
dc.authorscopusid56789896800
dc.authorscopusid44861103200
dc.authorscopusid26030049400
dc.authorscopusid57386826100
dc.authorscopusid57204462984
dc.authorscopusid6701575271
dc.authorscopusid14219156500
dc.contributor.authorBaysal, M.
dc.contributor.authorHindilerden, F.
dc.contributor.authorÜmit, E.G.
dc.contributor.authorDemir, A.M.
dc.contributor.authorKaradağ, F.K.
dc.contributor.authorSaydam, G.
dc.contributor.authorAkpınar, S.
dc.date.accessioned2024-08-25T18:39:24Z
dc.date.available2024-08-25T18:39:24Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: In recent years, new developments have been incorporated into daily practice in the management of immune thrombotic thrombocytopenic purpura (iTTP). In particular, clinical scoring systems could help clinicians with clinical decision-making and early recognition. However, older patients frequently present with more organ involvement and in unusual ways. The ways in which age could affect these clinical prediction scoring systems remain unclear. We evaluated the use of PLASMIC and French scores in patients over 60 years of age. Materials and Methods: We performed a retrospective cross-sectional analysis of patients over 60 years of age with a presumptive diagnosis of iTTP between 2014 and 2022 at 10 centers. We calculated PLASMIC and French scores and compared our data with a single-center analysis of younger patients presenting with thrombotic microangiopathy. Results: Our study included 30 patients over 60 years of age and a control group of 28 patients younger than 60 years. The diagnostic sensitivity and specificity of a French score of ?1 were lower in older patients compared to the control group (78.9% vs. 100% and 18.2% vs. 57.1%, respectively). The diagnostic sensitivity and specificity of a PLASMIC score of ?5 were 100% vs. 95% and 27.3% vs. 100% for the study group and control group, respectively. Our study showed a higher mortality rate in older patients compared to the control group (30% vs. 7.1%, p=0.043). Conclusion: For a limited number of patients (n=6), our results showed that rituximab can reduce mortality. Given that the reliability of clinical prediction scores for iTTP in older patients may be lower, more caution must be undertaken in interpreting their results. © 2023 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House.en_US
dc.identifier.doi10.4274/tjh.galenos.2023.2023.0295
dc.identifier.endpage257en_US
dc.identifier.issn1300-7777
dc.identifier.issue4en_US
dc.identifier.pmid37791641en_US
dc.identifier.scopus2-s2.0-85178658219en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage251en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2023.2023.0295
dc.identifier.urihttps://hdl.handle.net/11454/101365
dc.identifier.volume40en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Society of Hematologyen_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectAgeen_US
dc.subjectElderlyen_US
dc.subjectFrench scoreen_US
dc.subjectPLASMIC scoreen_US
dc.subjectThrombotic microangiopathyen_US
dc.subjectThrombotic thrombocytopenic purpuraen_US
dc.subjectbilirubinen_US
dc.subjectcreatinineen_US
dc.subjecteculizumaben_US
dc.subjecthaptoglobinen_US
dc.subjectlactate dehydrogenaseen_US
dc.subjectmethylprednisoloneen_US
dc.subjectrituximaben_US
dc.subjectvon Willebrand factor cleaving proteinaseen_US
dc.subjectvon Willebrand factor cleaving proteinaseen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectArticleen_US
dc.subjectcontrolled studyen_US
dc.subjectcross-sectional studyen_US
dc.subjectfemaleen_US
dc.subjectfrench scoreen_US
dc.subjecthumanen_US
dc.subjectimmune thrombotic thrombocytopenic purpuraen_US
dc.subjectinternational normalized ratioen_US
dc.subjectleukocyte counten_US
dc.subjectmaleen_US
dc.subjectmean corpuscular volumeen_US
dc.subjectmicroangiopathic hemolytic anemiaen_US
dc.subjectmortality rateen_US
dc.subjectpatient history of transplantationen_US
dc.subjectplasma exchangeen_US
dc.subjectplasmic scoresen_US
dc.subjectplatelet counten_US
dc.subjectreticulocyte counten_US
dc.subjectretrospective studyen_US
dc.subjectscoring systemen_US
dc.subjectsensitivity and specificityen_US
dc.subjectthrombocytopeniaen_US
dc.subjectthrombotic microangiopathyen_US
dc.subjectthrombotic thrombocytopenic purpuraen_US
dc.subjectidiopathic thrombocytopenic purpuraen_US
dc.subjectmiddle ageden_US
dc.subjectreproducibilityen_US
dc.subjectthrombosisen_US
dc.subjectthrombotic microangiopathyen_US
dc.subjectthrombotic thrombocytopenic purpuraen_US
dc.subjectADAMTS13 Proteinen_US
dc.subjectAgeden_US
dc.subjectCross-Sectional Studiesen_US
dc.subjectHumansen_US
dc.subjectMiddle Ageden_US
dc.subjectPurpura, Thrombocytopenic, Idiopathicen_US
dc.subjectPurpura, Thrombotic Thrombocytopenicen_US
dc.subjectReproducibility of Resultsen_US
dc.subjectRetrospective Studiesen_US
dc.subjectThrombosisen_US
dc.subjectThrombotic Microangiopathiesen_US
dc.titleImmune Thrombotic Thrombocytopenic Purpura in Elderly Patients: The Roles of PLASMIC and French Scoresen_US
dc.title.alternativeİleri Yaştaki İmmün Trombotik Trombositopenik Purpura Hastalarında; PLASMIC ve French Skorlamalarının Rolüen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu